Brief: Spyre Doses First Patient In Phase 2 SKYWAY Trial of SPY072, First Anti-TL1A Antibody for Rheumatic Diseases
15/09/2025 13:59
Sept 15 (Reuters) - Spyre Therapeutics Inc SYRE.O: SPYRE THERAPEUTICS DOSES FIRST PATIENT IN PIONEERING PHASE 2 SKYWAY BASKET TRIAL OF SPY072, THE FIRST ANTI-TL1A ANTIBODY STUDIED IN RHEUMATIC DISEASES Source text: ID:nGNX4r96GS Further company coverage: SYRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock